For the quarter ending 2025-09-30, BIXT had $11,355 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -282,725 | -1,318,197 |
| Amortization of ip | 4,236 | 4,360 |
| Debt discount amortization, incl. issuance of warrants | - | 0 |
| Stock-based compensation | 65,487 | 41,267 |
| Stock-based compensation affiliates | 125,547 | 27,795 |
| Shares due for debt conversion affiliates | - | 0 |
| Interest paid for note conversion | - | 0 |
| Change in fv of derivative | 264,796 | -497,350 |
| Shares due for debt conversion | - | 8,510 |
| Accounts payable and accrued expenses | 72,985 | 622,193 |
| Accounts payable and accrued expenses affiliates | 246,302 | -131,288 |
| Net cash used in operating activities | -41,474 | -248,010 |
| Investment in intangibles | 1,674 | 15,177 |
| Net cash used in investing activities | -1,674 | -15,177 |
| Proceeds from stock sales | - | 0 |
| Stock subscription for cash | 13,353 | - |
| Short-term loans | 2,000 | 0 |
| Proceeds from issuance of convertible notes payable | - | 0 |
| Short-term loans from affiliates | 39,150 | 261,177 |
| Net cash provided by financing activities | 54,503 | 261,177 |
| Net decrease in cash | 11,355 | -2,010 |
| Cash and cash equivalents at beginning of period | 5,154 | - |
| Cash and cash equivalents at end of period | 14,499 | - |
BIOXYTRAN, INC (BIXT)
BIOXYTRAN, INC (BIXT)